Jpmorgan Chase & CO Reata Pharmaceuticals Inc Transaction History

Jpmorgan Chase & CO

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	BUY	$79.22 - $105.37 $6.57 Million - $8.74 Million	82,980 Added 67.33%	206,223 $21 Million
Q1 2023 May 18, 2023	BUY	$30.85 - $93.17 $1.08 Million - $3.25 Million	34,856 Added 39.44%	123,243 $11.2 Million
Q1 2023 May 11, 2023	SELL	$30.85 - $93.17 $2.44 Million - $7.36 Million	-79,029 Reduced 47.21%	88,387 $8.04 Million
Q4 2022 Feb 13, 2023	BUY	$22.15 - $42.11 $760,985 - $1.45 Million	34,356 Added 25.82%	167,416 $6.36 Million
Q3 2022 Nov 14, 2022	BUY	$19.41 - $36.49 $1.72 Million - $3.24 Million	88,750 Added 200.29%	133,060 $3.35 Million
Q2 2022 Aug 11, 2022	BUY	$20.71 - $36.5 $334,425 - $589,402	16,148 Added 57.34%	44,310 $1.35 Million
Q1 2022 May 11, 2022	BUY	$24.12 - $39.6 $106,079 - $174,160	4,398 Added 18.51%	28,162 $923,000
Q4 2021 Feb 10, 2022	SELL	$25.61 - $110.96 $58,211 - $252,212	-2,273 Reduced 8.73%	23,764 $627,000
Q3 2021 Nov 12, 2021	BUY	$100.0 - $143.02 $2.6 Million - $3.72 Million	26,037 New	26,037 $2.62 Million

62.7K

Ticker RETA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,583,200
Description
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney diseas...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.